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Summary
Objective: Studies evaluating genetic markers for vas-
cular risk and risk of stroke are limited, and none of 
them evaluated obesity genes. The objective was to in-
vestigate the genetic markers related to obesity genes 
FTO and MC4R and the gene of type 2 diabetes mellitus 
TCF7L2 for their contribution to risk of stroke and tran-
sient ischemic attacks (TIA). Methods: We recruited 379 
consecutive patients with stroke/TIA and 379 healthy 
population-based controls. The single-nucleotide poly-
morphisms (SNPs) rs9937053 (FTO), rs2229616 (MC4R 
V103I), rs17782313 (188kb downstream of MC4R), and 
rs7903146 (TCF7L2) were evaluated for association with 
stroke using logistic regression analyses. Results: The 
odds ratios for stroke/TIA were 1.14 (95%CI 0.91–1.42) 
for rs9937053/FTO, 1.11 (95%CI 0.49–2.51) for rs2229616/
MC4R, 1.05 (95%CI 0.82–1.3) for rs17782313/MC4R, and 
0.99 (95%CI 0.78–1.25) for rs7903146/TCF7L2. Further 
exploration revealed that male patients with the T al-
lele of rs7903146/TCF7L2 had a worse clinical outcome 
compared with male patients carrying the C allele. Con-
clusion: The observed trends of obesity risk alleles for 
risk of stroke/TIA as well as the possible sex-specific 
differences in clinical outcomes found for the TCF7L2 
(rs7903146) require replication in future studies. Our 
study demonstrates that candidate gene studies for 
common stroke may benefit from focusing on polymor-
phisms that predispose to vascular risk.
Introduction
Stroke is the third leading cause of death in adults in the 
Western world. It imposes a significant economic burden on 
the society and individual patients [1–5]. The two principal 
types of stroke are ischemic and hemorrhagic stroke. Both are 
associated with vascular risk factors such as chronic arterial 
hypertension, type 2 diabetes mellitus (T2DM), hyperlipi-
demia, and obesity [6–8]. Studies in twins, families, and ani-
mal models support the role of genetic factors in the etiology 
of stroke [9]. However, the extent of genetic contribution to 
the risk of stroke is uncertain.
Mendelian disorders associated with stroke include meta-
bolic disorders of inborn origin, hemoglobinopathies, dyslipo-
proteinemias, and cardioembolic disorders. Examples of such 
are sickle cell disease, cerebral autosomal dominant arteriopa-
thy with subcortical infarct and leukoencephalopathy (CA-
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DASIL), mitochondrial disorders such as mitochondrial en-
cephalopathy with lactic acidosis and stroke-like episodes 
(MELAS), familial atrial myxoma, and Fabry’s disease [9]. 
However, all these well recognized and phenotypically distinct 
causes for stroke include only a small minority of stroke cases. 
Defining the genetic basis of common stroke, which is 
thought to have a polygenic basis, has proven more challeng-
ing [10]. Most genetic studies which evaluated candidate 
genes in common stroke focused on genes involved in throm-
bosis and coagulation [10]. The majority of these candidate 
genes were evaluated initially in ischemic heart disease. 
Genes involved in the biology of well-known risk factors for 
stroke (e.g. arterial hypertension, hyperlipidemia, T2DM, and 
obesity) have received limited attention. To the best of our 
knowledge, studies evaluating the role of candidate genes of 
obesity in the formation of stroke are lacking to date. Data on 
the relation of T2DM genes with stroke are scarce and incon-
sistent [11, 12].
The objective of the Mannheim-Heidelberg Stroke Study 
was to evaluate confirmed genetic markers of the obesity 
genes ‘fat mass and obesity associated’ (FTO) and the 
‘melanocortin 4 receptor’ (MC4R) as well as the T2DM sus-
ceptibility gene ‘transcription factor 7-like 2’ (TCF7L2) for 
their contribution to the risk of stroke and transient ischemic 
attacks (TIAs). The phenotype analysis of the study popula-
tion had shown a positive association between anthropomet-
ric measures of obesity and increased risk of stroke/TIA [8].
Patients and Methods
Study Design
The Mannheim-Heidelberg Stroke Study is a case-control genetic study 
of the disease-oriented Genome Network ‘Obesity and Related Disor-
ders’, which is a part of the German National Genome Research Network 
plus (NGFNplus). For a detailed description of the study design, we refer 
to our previous publication [8]. In brief, the study sample consisted 379 
consecutive cases of stroke and TIAs and 379 healthy controls. Cases 
were recruited in the Departments of Neurology of the University Hospi-
tals of Mannheim and Heidelberg between February 1, 2005 and January 
31, 2006. Those patients with recurrent cerebrovascular events or a his-
tory of cerebrovascular events prior to initiation of the study were not 
excluded. Clinical records were incomplete for 22 out of 401 initially 
 recruited cases so that these cases were excluded from the analysis. Re-
gional controls without a history of cerebrovascular disease were fre-
quency-matched for age and sex using the database of 25,540 participants 
of the population-based cohort EPIC-Heidelberg [13]. For control selec-
tion, we draw individuals from the following age groups: <50, 50–55, 
56–60, 61–65, 66–70, and >70 years. Note that the age range for the cases 
was between 25 and 90 years, whereas the age range of controls was be-
tween 45 and 75 years only. The study was approved by the local ethics 
committee, and all participants gave informed consent. Thus, patients 
with impaired conciousnes or severe aphasia had to be excluded because 
no informed consent could be obtained in those instances.
Clinical Evaluation
Each patient received a complete medical and neurological examination, 
CT and/or MRI of the head. The diagnosis of stroke was defined according 
to the World Health Organization (WHO) [14]. The following markers of 
obesity were evaluated in less than 48 h after admission: BMI, waist-to-hip 
ratio (WHR), waist circumference, and waist-to-stature ratio (WSR). BMI 
was calculated as weight (kilograms) divided by height (meters squared). 
WHR was calculated as waist divided by hip circumference. Waist circum-
ference (cm) was measured at the level of the umbilicus. Hip circumference 
(cm) was measured at the level of the bilateral greater trochanters. WSR 
was defined as waist circumference divided by body height. The vascular 
risk factors included T2DM (fastening blood glucose ≥ 126 mg/dl or use of 
insulin or oral hypoglycemic agents), hypertension (systolic blood pressure 
≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg or treatment with 
antihypertensive agents), hyperlipidemia (total serum cholesterol level 
≥ 240 mg/dl or use of antihyperlipidemic agents), and physical inactivity 
(sport activities of less than 20 min 2 times per week).
Clinical outcomes were measured using the National Institute of Health 
Stroke Scale (NIHSS) and modified Rankin scale (mRS), which are valid 
and reliable measures of stroke outcome [15, 16]. The NIHSS is a stan-
dardized measure of stroke severity and level of stroke impairment. It is 
one of the most frequently used scales in stroke clinical trials. The NIHSS 
scores range from 0 to 42, with increasing scores indicating increasing 
stroke severity [16]. The mRS is a measure of the functional status and 
disability. Its scores range from 0 (no impairment) to 5 (severe impair-
ment) [15].
Genotyping 
The following single nucleotide polymorphisms (SNPs) were used in the 
analysis: rs17782313 (MC4R, obesity risk allele C) [17], rs2229616 (MC4R 
V103I, obesity risk allele A) [18], rs9937053 (FTO, obesity risk allele A) 
[19], rs7903146 (TCF7L2, T2DM risk allele T) [20].
The rationale for use of these SNPs in the analysis was based on fol-
lowing: The association of the common genetic variants of FTO and 
MC4R with BMI was shown in large-scale genetic studies [17, 19, 21]. The 
MC4R SNP rs17782313 is in high linkage disequilibrium with a SNP that 
is associated with waist circumference and insulin resistance [21]. The 
TCF7L2 polymorphism rs7903146 is associated with T2DM; interestingly, 
this major T2DM risk allele is also weakly negatively associated with 
obesity [22]. Recently, the rs7903146 T allele has been shown to be asso-
ciated with severity and mortality of coronary artery disease [23]. 
Genomic DNA was isolated from EDTA-anticoagulated blood using 
standard procedures. The FTO SNP rs9939609 and the TCF7L2 SNP 
rs79031746 were genotyped using tetra-ARMS-PCR as described previ-
ously [24, 25]. For MC4R rs2229616 (V103I) DNA samples were geno-
typed as described previously [26], and rs17782313 was genotyped using 
TaqMan® SNP genotyping assay C_32667060_10 (Applied Biosystems, 
Darmstadt, Germany) with standard conditions; call rates were ≥99%, 
with 100% concordance of duplicates.
Statistical Analysis 
All genotype distributions (in cases, controls and in the sex-stratified sub-
samples) were tested for deviations from Hardy-Weinberg equilibrium 
using the PLINK software (Version 1.04), and no evidence for such de-
viations was detected (all p >> 0.12). All phenotypes were analyzed by 
either linear or logistic regression analyses (crude (model 1 in table 3) and 
 (simultaneously; model 2 in table 3) adjusted for the covariates age 
(years), sex (female/male), history of hypertension (yes/no), history of 
diabetes (yes/no), physical inactivity (yes/no), and smoking (yes/no)). Ex-
cept for MC4R (rs2229616), where a dominant mode of inheritance was 
assumed, each SNP was analyzed under an (log-)additive genetic model. 
Power calculations were done with the software QUANTO (Version 
1.2.3, http://hydra.usc.edu/gxe). 379 case-control pairs were estimated to 
yield a power of 83% to detect log-additive odds ratios (ORs) of 1.4 for a 
minor allele frequency of 25% (based on HapMap CEU data for 
rs7903146) and  = 0.05 (two-sided). Confidence intervals were calculated 
with coverage of 95% (abbreviated 95% CI), and accordingly the level  
for each test was 0.05 (two-sided). Unless otherwise stated, all reported 
p values are nominal, two-sided, and not adjusted for multiple testing.
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other vascular risk factors than controls. The mean NIHSS 
score at admission was 4.5 ± 3.9 (median 3) in male patients 
and 5.1 ± 4.5 (median 4) in female patients. 
The genotype frequencies in cases and controls are shown 
in table 2. The T allele of TCF7L2 showed a positive asso-
ciation with T2DM (OR 1.35, 95% CI 1.02–1.80), which re-
mained significant after adjustment for age, sex ,and vascular 
risk factors (OR 1.36, 95% CI 1.01–1.84). For all other mark-
ers, though not statistically detectable, we observed similar 
directions of allelic effects for BMI and WHR as reported 
previously (e.g. increased BMI (regression coefficient 0.15, 
Results
We included 379 cases with stroke (ischemic stroke n = 301, 
intracerebral hemorrhage (ICH) n = 37, or TIA n = 41) of 
whom 141 were female (37.2%). Demographics and distri-
bution of known vascular risk factors are shown in table 1. 
Due to the fact that among the controls no individual was 
older than 75 years, the mean age of cases was slightly higher 
than the mean age of controls (67.3 ± 12.2 vs. 65.0 ± 8.3 years; 
p = 0.02). Cases had higher prevalences of obesity (29.8% of 
cases (n = 113) vs. 20.8% of controls (n = 79); p < 0.01) and 











mean ± SD % yes mean ± SD % yes mean ± SD % yes mean ± SD % yes
Age, years 65.0 ± 9.0 66.9 ± 10.9 0.018 65.0 ± 9.0 68.0 ± 14.1 0.021
Weight, kg 84.4 ± 12.0 84.7 ± 12.7 0.934 69.9 ± 11.1 74.8 ± 18.4 0.071
Height, cm 175.3 ± 6.6 173.9 ± 7.1 0.016 161.5 ± 6.2 161.7 ± 6.4 0.580
WC, cm 98.5 ± 10.3 103.6 ± 11.1 <0.001 85.0 ±11.2 98.2 ± 15.5 <0.001
HC, cm 102.5 ± 6.4 103.5 ± 10.6 0.336 102.7 ± 8.3 105.3 ± 12.1 0.104
WHR 1.0 ± 0.7 1.00 ± 0.08 <0.001 0.8 ± 0.8 0.93 ± 0.1 <0.001
BMI 27.5 ± 3.6 28.0 ±3.7 0.121 26.8 ± 4.3 28.6 ± 6.5 0.087
WSR 0.52 ± 0.08 0.60 ± 0.07 <0.001 0.52 ± 0.08 0.61 ± 0.10 <0.001
PIN 44.0 82.5 <0.001 41.8 87.2 <0.001
Smoking 16.3 30.2 <0.001 12.1 24.8 <0.001
AHTN 49.0 84.3 <0.001 49.6 80.4 <0.001
T2DM 11.9 30.9 <0.001  9.5 30.7 <0.001
HLP 55.6 50.4 0.087 56.0 53.9 0.322
AHTN = Arterial hypertension; HC = hip circumference; HLP = hyperlipidemia; PIN = physical inactivity; WC = waist circumference.
*Descriptive two-sided p value of the Wilcoxon-Mann-Whitney test.
Table 2. Genotype distributions in cases and controls
SNP (gene) Genotypes Men Women
number of  
cases (%)
number of  
controls (%)
p value* number of  
cases  (%)
number of  
controls (%)
p value*
rs9937053 (FTO) AA  33 (16.4)  40 (17.3) 0.26  20 (16.9)  19 (14.0) 0.73
AT 104 (51.7) 102 (44.2)  64 (54.2)  73 (53.7)
TT  64 (31.8)  89 (38.5)  34 (28.8)  44 (32.4)
rs17782313 (MC4R) CC  12 (6.0)  15 (6.6) 0.87  10 (8.5)   4 (3.0) 0.18
CT  78 (38.9)  92 (40.7)  46 (40.0)  53 (39.9)
TT 111 (55.1) 119 (52.7)  62 (52.5)  76 (57.1)
rs2229616 (MC4R) GG 205 (96.7) 226 (96.6) 1.00 121 (96.0) 136 (97.1) 0.74
GA   7 (3.3)   8 (3.4)   5 (4.0)   4 (2.9)
rs7903146 (TCF7L2) CC 108 (50.9) 114 (49.1) 0.92  60 (47.6)  69 (50.7) 0.71
CT  87 (41.0) 100 (43.1)  58 (46.0)  56 (41.2)
TT  17 (8.0)  18 (7.8)   8 (6.3)  11 (8.1)
*Descriptive two-sided p value of Fishers exact test.
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1.11 (95% CI 0.49–2.51; p = 0.80) for MC4R V103I rs2229616 
A-allele, 1.05 (95% CI 0.82–1.34; p = 0.72) for MC4R variant 
rs17782313 C-allele, and 0.99 (95% CI 0.78–1.25; p = 0.92) for 
rs7903146 (TCF7L2). After adjustment (model 2) the obser-
vation of the absence of an effect was underlined. In addition, 
explorative stratification by sex did not show any significant 
sex-specific associations (table 3).
p = 0.52) and larger WHR (regression coefficient 0.003, 
p = 0.54) for the obesity risk allele of the FTO polymorphism 
rs9937053). 
The associations between variants of the three candidate 
genes and risk of stroke were investigated using logistic re-
gression analysis (table 3). The ORs for stroke or TIA were 
1.14 (95% CI 0.91–1.42; p = 0.25) for FTO rs9937053 A-allele, 
Table 3. ORs for the associations between genotype and risk of stroke/TIA
SNP (gene) Effect allele Genetic model Model 1* Model 2**
OR 95% CI p value OR 95% CI p value
All participants
rs9937053 (FTO) A ADD 1.14 0.91–1.42 0.25 1.11 0.85–1.44 0.46
rs17782313 (MC4R) C ADD 1.05 0.82–1.34 0.72 1.06 0.79–1.42 0.68
rs2229616 (MC4R) A DOM 1.11 0.49–2.51 0.80 0.80 0.31–2.08 0.64
rs7903146 (TCF7L2) T ADD 0.99 0.78–1.25 0.92 0.85 0.64–1.13 0.26
Males
rs9937053 (FTO) A ADD 1.13 0.86–1.48 0.39 1.1 0.79–1.52 0.58
rs17782313 (MC4R) C ADD 0.92 0.67–1.25 0.59 0.90 0.63–1.31 0.61
rs2229616 (MC4R) A DOM 0.96 0.34–2.71 0.95 0.53 0.16–1.74 0.29
rs7903146 (TCF7L2) T ADD 0.96 0.72–1.29 0.80 0.82 0.58–1.17 0.28
Females
rs9937053 (FTO) A ADD 1.16 0.80–1.69 0.43 1.16 0.73–1.84 0.54
rs17782313 (MC4R) C ADD 1.32 0.87–2.00 0.19 1.38 0.83–2.28 0.21
rs2229616 (MC4R) A DOM 1.41 0.37–5.35 0.62 1.74 0.32–9.60 0.52
rs7903146 (TCF7L2) T ADD 1.04 0.70–1.53 0.86 0.9 0.56–1.46 0.68
ADD = Additive mode of inheritance; DOM = dominant mode of inheritance.
*Model 1: not adjust; crude estimates.
**Model 2: simultaneously adjusted for age (years) and sex (female/male), history of hypertension (yes/no), history of diabetes (yes/no), physical inac-
tivity (yes/no) and smoking (yes/no). 
Table 4. Associations between genotype and risk of different cerebrovascular events
SNP (gene) Effect allele Genetic model Model 1* Model 2**
OR 95% CI p value OR 95% CI p value
TIA
rs9937053 (FTO) A ADD 1.57 0.94–2.59 0.08 1.47 0.87–2.49 0.15
rs2229616 (MC4R) A DOM NA NA NA NA NA NA
rs7903146 (TCF7L2) T ADD 1.11 0.65–1.89 0.72 1.07 0.62–1.86 0.81
Ischemic stroke
rs9937053 (FTO) A ADD 1.03 0.82–1.29 0.83 0.97 0.74–1.27 0.84
rs2229616 (MC4R) A DOM 1.19 0.52–2.72 0.68 0.94 0.36–2.45 0.90
rs7903146 (TCF7L2) T ADD 0.95 0.75–1.21 0.69 0.82 0.61–1.08 0.15
ICH
rs9937053 (FTO) A ADD 1.12 0.68–1.86 0.65 1.10 0.64–1.9 0.74
rs2229616 (MC4R) A DOM 1.75 0.39–7.74 0.46 1.47 0.32–6.74 0.62
rs7903146 (TCF7L2) T ADD 1.09 0.64–1.84 0.76 1.07 0.63–1.82 0.80
ADD = Additive mode of inheritance; DOM = dominant mode of inheritance; NA = not available.
*Model 1: not adjust; crude estimates.
**Model 2: adjusted for age (years) and sex (female/male), history of hypertension (yes/no), history of diabetes (yes/no), physical inactivity (yes/no) 
and smoking (yes/no).
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Large-scale studies searched for candidate genes for obes-
ity and found associations with common genetic variants of 
the genes FTO and MC4R [17, 19, 21]. The minor (A) allele 
of the most common intragenic variant of MC4R (rs2229616) 
was shown to be associated with decreased BMI [28]. The role 
of MC4R as genetic risk factor contributing to the develop-
ment of other common risk factors of cerebrovascular disease 
(e.g. insulin resistance and metabolic syndrome) was dis-
cussed in the recent years [21, 29]. However, genetic studies 
have so far not evaluated the association between MC4R and 
the risk of cerebrovascular disease outcomes directly. Despite 
the evidence from previous studies on the association of 
MC4R with cerebrovascular risk factors, the variant rs2229616 
was not associated with risk of stroke/TIA in the present 
study.
FTO has also been shown to be associated with obesity 
and other cerebrovascular risk factors such as the metabolic 
syndrome [30], and a possible role in atherosclerosis is under 
discussion. Kivimaki et al. [31] showed that individuals with 
the A allele of the FTO polymorphism rs9939609 had a trend 
towards increased intima-media thickness of the carotid ar-
tery, which is a clinical marker of atherosclerosis. To the best 
of our knowledge, none of previous studies evaluated the 
FTO variants with a focus on cerebrovascular disease. Our 
study did not observe any evidence for an association be-
tween FTO and risk of stroke. Interestingly, we found a weak 
association between FTO rs9939609 and risk of TIA. There-
fore, further studies should focus on evaluation of rs9939609 
in risk of TIA.
T2DM is one of the most important risk factors for cere-
brovascular disease [20, 32]. The TCF7L2 polymorphism 
rs7903146 has been consistently associated with T2DM in dif-
The analysis of different types of cerebrovascular disease 
showed a weak association of FTO rs9937053 A-allele with in-
creased risk of TIA (OR 1.57, 95% CI 0.94–2.59; p = 0.08) 
(table 4). The OR decreased after adjustment (1.47, 95% CI 
0.87–2.49; p = 0.15). For ischemic stroke and ICH no evidence 
for genetic associations was found. 
Different genotypes were compared for association with 
stroke severity measured by NIHSS and mRS at admission 
and at follow-up on day 7 after admission. At admission, no 
differences in the stroke severity have been detected for the 
studied genotypes. The clinical outcome on day 7 was worse 
in male patients with allele T of rs7903146 (TCF7L2) com-
pared to male patients with the C allele at this marker (mRS 
p = 0.02; NIHSS p = 0.04). There were no statistically signi-
ficant differences in clinical outcome of female patients. The 
comparison of clinical outcomes by different genotypes re-
lated to FTO an MC4R did not provide evidence for statisti-
cally significant differences (table 5). We also did not find any 
associations between studied genotypes and the age at which 
the cerebrovascular event occurred (data not shown).
Discussion
We evaluated the confirmed variants in obesity and T2DM 
genes FTO, MC4R and TCF7L2 with regard to their potential 
role in the risk of stroke/TIA. Obesity is an important vascu-
lar risk factor and its role in stroke has been intensely investi-
gated in the last years [27]. For example, we have reported an 
association between abdominal obesity and increased risk of 
stroke/TIA [8] which has been replicated in two population-
based studies [6, 7]. 
Table 5. Sex-specific clinical outcome scores 7 days after stroke/TIA stratified by genotype
SNP (gene) mRS mean (median) ± SD NIHSS mean (median) ± SD
men p value women p-value men p value women p value
rs9937053 (FTO) 
 TT 1.4 (2) ± 1.5 0.22 2.7 (2) ± 2.6 0.79 1.9 (2) ± 2.6 0.24 5.3 (3) ± 5.7 0.85
 AT 1.7 (2) ± 1.6 1.9 (2) ± 1.8 2.3 (2) ± 2.8 3.0 (3) ± 3.9
 AA 2.0 (2) ± 1.6 2.0 (2) ± 1.8 2.9 (2) ± 3.3 3.5 (3) ± 4.8
rs17782313 (MC4R) 
 CC 1.9 (2) ± 1.8 0.88 2.3 (2) ± 2.1 0.67 3.0 (3) ± 3.3 0.78 3.7 (3) ± 4.0 0.80
 CT 1.8 (2) ± 1.7 1.8 (2) ± 1.7 2.7 (3) ± 3.4 2.8 (3) ± 3.5
 TT 1.7 (2) ± 1.5 2.1 (2) ± 1.8 2.2 (3) ± 2.7 3.6 (3) ± 4.6
rs2229616 (MC4R)
 GG 1.8 (1) ± 1.6 0.58 2.1 (2) ± 1.8 0.58 2.5 (3) ± 3.0 0.50 3.6 (2) ± 4.5 0.66
 GA 2.0 (1) ± 1.4 1.6 (2) ± 1.7 3.1 (3) ± 3.1 2.2 (2) ± 2.5
rs7903146 (TCF7L2)
 CC 1.5 (1) ± 1.4 0.02 2.1 (2) ±1.8 0.61 2.0 (2) ± 2.5 0.04 3.4 (3) ± 4.1 0.34
 CT 2.1 (2) ± 1.7 2.1 (2) ±1.9 3.1 (3) ± 3.2 3.4 (3) ± 4.9
 TT 1.9 (2) ± 1.7 1.4 (2) ±1.6 3.1 (3) ± 4.0 2.3 (3) ± 1.7
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TIA. Additionally, very severely affected patients or patients 
with global aphasia were not included in this study as their 
informed consent could not be obtained. This may have 
 limited the number of severe strokes so that these are under-
represented. There were only individuals aged 45–75 years 
among the controls; so exact age matching was not possible. 
In order to avoid a systematic error of data, the plausibility 
proof was conducted by using only the exact age match for 
cases aged 45–75 years. This analysis confirmed all main re-
sults as robust [8]. Finally, we evaluated only three candidate 
genes of obesity and T2DM for their impact on stroke/TIA. 
MC4R and FTO are the most important obesity genes at the 
time of the study conduct [17, 19, 21], whereas TCF7L2 is 
the most important genetic factor for T2DM. In or near the 
above mentioned candidate genes, we evaluated alleles of 
SNPs, which are known to be robustly associated with obes-
ity or T2DM susceptibility despite the fact that these vari-
ants may not be the variants with a functional effect. Cur-
rently, a number of new candidate genes are suggested that 
may come under investigation soon [42, 43]. 
In conclusion, we evaluated variants of three candidate 
genes for obesity and T2DM, MC4R, FTO and TCF7L2, for a 
potential contribution to stroke susceptibility and observed 
no significant associations. In an explorative, sex-stratified 
analysis, we observed a weak association of the T allele of 
TCF7L2 to clinical outcomes which requires replication. Fu-
ture studies on genetics of common stroke should concentrate 
on evaluation of genes predisposing to cerebrovascular risk 
factors, such as obesity and T2DM, and consider the assess-
ment of genetic determinants of clinical outcome.
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ferent populations [33]. In addition, the same variant has been 
reported to be associated with obesity and the severity and 
mortality of cardiovascular disease [23]. However, data on its 
role in vascular diseases are inconsistent [34]. We observed 
that allele T of TCF7L2 showed a positive association with 
T2DM which is consistent with the results of previous studies 
[33]. However, we did not observe any evidence for an asso-
ciation between TCF7L2 and risk of stroke. 
Little is known about the genetic determinants of outcome 
after stroke. The associations with survival and disability fol-
lowing stroke were found for genotypes of interleukin-1 re-
ceptor antagonist, interleukin-6, and insulin-like growth factor 
I [35–37]. Currently, genetic determinants of stroke outcome 
are being investigated in the Genes Affecting Stroke Risk and 
Outcome Study (GASROS) [38]. Our study found a sex-spe-
cific influence of the T allele of TCF7L2 on the functional 
outcome after stroke measured by both mRS and NIHSS. 
This corresponds with data from other stroke studies showing 
that hyperglycemia is associated with a poor clinical outcome 
in stroke patients [39].
Strengths of our study are that we used a case-control 
 design with controls ascertained from a population-based 
study. Cases were recruited consecutively in two large neu-
rological clinics with a well-defined catchment area of ap-
proximately 800,000 inhabitants. The moderate sample size 
of our study is comparable to the samples sizes of other 
 genetic studies in stroke (549 cases in the ARIC study [34], 
540 cases in the Rotterdam Study [40], 297 cases in the 
Stroke Prevention in Young Women Study [41]). However, 
this study did not have sufficient statistic power to identify 
ORs for stroke that are in the order of 1.2 or lower and 
should be considered as a pilot study on the role of obesity 
genes (FTO, MC4R, and TCF7L2) in the risk of common 
stroke. In order to substantiate the possible association be-
tween FTO and the risk of stroke/TIA, a sample size of at 
least about 3,000 case-control pairs as based on the observed 
effect (OR ~ 1.1) and allele frequency (~40%) would be nec-
essary for a power of 80%. As case-control studies focusing 
on stroke with such a sample size are rare, future meta-anal-
yses will be necessary to address the question of potential 
smaller effects of the three investigated markers of the three 
genes FTO, MC4R and TCF7L2 on the risk of stroke or 
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